Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus
Palabras clave :
Cellular medicaments
Cell-based therapy
Clinical trials
Diabetes
Critical limb ischemia
Cost-effective
Fecha de publicación :
2019
Editorial :
Frontiers Media SA
Nota:
This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Cita:
Soria-Juan, B. (Bárbara); Escacena, N. (Natalia); Capilla-González, V. (Vivian); et al. "Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus". Frontiers in Immunology. 10 (1151), 2019,
Aparece en las colecciones:
Estadísticas e impacto
0 citas en
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.